ID

13058

Descripción

An Open Protocol for the Compassionate Use of Thalidomide; ODM derived from: https://clinicaltrials.gov/show/NCT00081757

Link

https://clinicaltrials.gov/show/NCT00081757

Palabras clave

Versiones (1)
  1. 13/1/16 13/1/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

13 de enero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Multiple Myeloma NCT00081757

Inglés

Eligibility Multiple Myeloma NCT00081757

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
all patients must have a confirmed malignancy which can be classified as locally advanced or distant metastatic disease and must have either 1) failed on standard therapy or 2) have disease for which in the opinion of the investigator, no adequate standard +therapy exists.
Descripción

multiple myeloma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0026764
patients must be 18 years of age or older. women of childbearing potential must have a negative pregnancy test and fertile women and men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
Descripción

age, pregnany, contraception

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0032961
UMLS CUI [3]
C0700589
patients must sign an informed consent to participate in this study.
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
swog performance status 0-3, unless related to cancer pain.
Descripción

swog performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1518965
before starting treatment, women of childbearing potential should have a negative pregnancy test performed within 24 hours prior to beginning therapy.
Descripción

pregnancy test

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
pregnancy testing is not required for 1) women who have been post-menopausal for at least 2 years with no menses, 2) women who have had a hysterectomy.
Descripción

post-menopausal or hysterectomy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0020699
patients must have adequate hematologic function as demonstrated by total white blood count > or = 2000/mm3, adequate renal function as demonstrated by serum creatinine < or = 3.0 mg/dl, and adequate hepatic function as demonstrated by bilirubin < or =1.5 mg/dl and transaminases < or =4 x uln.
Descripción

hematologic, renal and hepatic function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023508
UMLS CUI [2]
C0201976
UMLS CUI [3]
C1278039
UMLS CUI [4]
C0002594
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients must not be eligible for any uams participating clinical trial of higher priority.
Descripción

patients must not be eligible for any uams participating clinical trial of higher priority.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
Volver a la parte superior de la página

Similar models

Eligibility Multiple Myeloma NCT00081757

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
multiple myeloma
Item
all patients must have a confirmed malignancy which can be classified as locally advanced or distant metastatic disease and must have either 1) failed on standard therapy or 2) have disease for which in the opinion of the investigator, no adequate standard +therapy exists.
boolean
C0026764 (UMLS CUI [1])
age, pregnany, contraception
Item
patients must be 18 years of age or older. women of childbearing potential must have a negative pregnancy test and fertile women and men must use a medically acceptable means of birth control while on study and for 6 months thereafter.
boolean
C0001779 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
informed consent
Item
patients must sign an informed consent to participate in this study.
boolean
C0021430 (UMLS CUI [1])
swog performance status
Item
swog performance status 0-3, unless related to cancer pain.
boolean
C1518965 (UMLS CUI [1])
pregnancy test
Item
before starting treatment, women of childbearing potential should have a negative pregnancy test performed within 24 hours prior to beginning therapy.
boolean
C0032961 (UMLS CUI [1])
post-menopausal or hysterectomy
Item
pregnancy testing is not required for 1) women who have been post-menopausal for at least 2 years with no menses, 2) women who have had a hysterectomy.
boolean
C0232970 (UMLS CUI [1])
C0020699 (UMLS CUI [2])
hematologic, renal and hepatic function
Item
patients must have adequate hematologic function as demonstrated by total white blood count > or = 2000/mm3, adequate renal function as demonstrated by serum creatinine < or = 3.0 mg/dl, and adequate hepatic function as demonstrated by bilirubin < or =1.5 mg/dl and transaminases < or =4 x uln.
boolean
C0023508 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0002594 (UMLS CUI [4])
Item Group
C0680251 (UMLS CUI)
patients must not be eligible for any uams participating clinical trial of higher priority.
Item
patients must not be eligible for any uams participating clinical trial of higher priority.
boolean
C2348568 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial